Sputnik V, Russia’s coronavirus vaccine, arrives in India for human clinical trial


Sputnik V, Russia coronavirus vaccine
Image Source : AP

Sputnik V, Russia’s coronavirus vaccine, arrives in India for human clinical trial

Russia’s coronavirus vaccine, Sputnik V, the primary vaccine in the world for COVID-19  has arrived in India following the nod to Pharma main Dr Reddy’s Laboratories to conduct an adaptive section 2/3 human clinical trial for the vaccine in the nation.

In a video that surfaced on media, containers with logos of Dr Reddy’s and Sputnik V being unloaded from a small truck was seen.

On Wednesday, Russia’s National Research Centre for Epidemiology and Microbiology and the Russian Direct Investment Fund introduced that the Sputnik V vaccine demonstrated excessive efficacy — 92 per cent.

On September 4, The Lancet, considered one of world’s main medical journals, revealed a analysis paper on the outcomes of Phase I and Phase II clinical trials of the vaccine that confirmed no critical adversarial occasions and efficient immune response of these vaccinated.

Requests for greater than 1.2 billion doses of Sputnik V vaccine got here from over 50 international locations. The vaccine provides for the worldwide market might be produced by RDIF’s worldwide companions in India, Brazil, China, South Korea and different international locations

Earlier this October, Dr Reddy’s and Russia Direct Investment Fund (RDIF) acquired approval from the Drugs Controller General of India (DCGI) to conduct an adaptive section 2/3 human clinical trial for the Sputnik V vaccine in India.

“The government is committed to fast-track clinical development of COVID vaccine candidates and provide facilitation to accelerate market readiness of a suitable vaccine,” mentioned Renu Swarup, Secretary, DBT and Chairperson, BIRAC.

On August 11, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and have become the world’s first registered vaccine in opposition to Covid-19 based mostly on the human adenoviral vector platform.

(With Inputs from IANS)





Source link

About The Author